Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2023; 81(07): 616-623
DOI: 10.1055/s-0043-1769124
Original Article

Outcomes of recurrent stroke in patients with atrial fibrillation according to presumed etiology

Desfecho de AVC recorrente em pacientes com fibrilação atrial de acordo com etiologia presumida
Bruno Bacellar Pedreira 
1   Harvard Medical School, Massachusetts General Hospital, Department of Neurology, Boston, United States.
2   Universidade Federal da Bahia, Hospital Universitario Professor Edgard Santos, Programa de Pós-Graduação em Ciências da Saúde, Salvador BA, Brazil.
,
Korilyn Sauser Zachrison 
3   Harvard Medical School, Massachusetts General Hospital and Boston, Department of Emergency Medicine, Boston, United States.
,
Aneesh Singhal 
1   Harvard Medical School, Massachusetts General Hospital, Department of Neurology, Boston, United States.
,
Zhiyu Yan 
1   Harvard Medical School, Massachusetts General Hospital, Department of Neurology, Boston, United States.
,
Jamary Oliveira-Filho 
2   Universidade Federal da Bahia, Hospital Universitario Professor Edgard Santos, Programa de Pós-Graduação em Ciências da Saúde, Salvador BA, Brazil.
,
Lee H. Schwamm 
1   Harvard Medical School, Massachusetts General Hospital, Department of Neurology, Boston, United States.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Atrial fibrillation (AF) is a potent risk factor for stroke. The presence of competing etiologies can modify disease outcomes and demand different treatment strategies.

Objectives The primary purpose of the study was to examine the differences in outcomes for patients with AF admitted with a recurrent stroke, stratified according to the presumed etiology of the stroke.

Methods We analyzed AF patients admitted for a recurrent ischemic stroke in an academic comprehensive stroke center. Recurrent strokes were categorized as “Cardioembolic”, meaning AF without any competing mechanism, versus “Undetermined” etiology due to competing mechanisms. We used logistic regression to test the association between recurrent stroke etiology and favorable outcome (discharge home), after accounting for important covariates.

Results We included 230 patients, with a mean age 76.9 (SD ± 11.3), 52.2% male, median National Institute of Health Stroke Scale (NIHSS) score of 7 (IQR 2–16). Patients with cardioembolic stroke (65.2%) had higher median NIHSS 8.5 (3–18) versus 3 (1–8) and were more likely to be treated with reperfusion therapies. The favorable outcome was reached by 64 patients (27.8%), and in-hospital mortality was 15.2% overall. After adjustment, there was no difference in outcome between patients with cardioembolic versus undetermined stroke etiology (odds ratio for discharge home: 1.41; 95% CI: 0.65–3.15).

Conclusions In this single-center sample of AF patients with history of stroke, there was no difference in discharge outcomes between those with cardioembolic and those with undetermined stroke etiology. This question warrants examination in larger samples to better understand the importance of the stroke mechanism and secondary prophylaxis.

Resumo

Antecedentes Fibrilação atrial (FA) é um fator de risco importante para AVC. A presença de mecanismos concorrentes para o AVC pode modificar o desfecho e demandar estratégias de tratamento diferentes.

Objetivos O objetivo primário do estudo foi examinar diferenças no desfecho de pacientes com FA admitidos por um AVC recorrente, sendo estratificados de acordo com a etiologia presumida do AVC.

Métodos Nós analisamos pacientes com FA admitidos por conta de AVC recorrente em um centro acadêmico terciário de AVC. Os casos de AVC recorrentes foram classificados como “Cardioembólicos”, sendo FA sem outros mecanismos alternativos, versus aqueles de etiologia “Indeterminada” por conta de mecanismos concorrentes. Foi usada regressão logística para testar a associação entre a etiologia do AVC recorrente e desfecho favorável (alta direto para casa) após controle para covariáveis importantes.

Resultados Nós incluímos 230 pacientes, com uma idade média 76,9 anos (DP ± 11.3), 52.2% homens, com um escore mediano do National Institute of Health Stroke Scale (NIHSS) de 7 (IIQ 2–16). Pacientes com AVC cardioembólicos (65,2%) tiveram um escore de NIHSS mediano mais alto 8,5 (3–18) versus 3 (1–8), e com maior chance de tratamento com terapias de reperfusão. O desfecho favorável ocorreu em 64 pacientes (27,8%) e a mortalidade institucional foi de 15,2% no total. Após ajustes, não encontramos diferença no desfecho entre pacientes com AVC cardioembólico versus AVC de etiologia indeterminada (odds ratio para alta para casa: 1,41; 95% IC: 0,65–3,15).

Conclusões Nessa amostra de pacientes com FA e história de AVC recorrente de centro único, não houve diferença no desfecho de alta entre aqueles com AVC cardioembólico e aqueles com etiologia indeterminada. Essa questão deve ser examinada em amostras maiores para melhor compreender a importância do mecanismo do AVC e a profilaxia secundária.

Keywords

Ischemic Stroke - Atrial Fibrillation - Embolic Stroke - Anticoagulants

Palavras-chave

AVC Isquêmico - Fibrilação Atrial - AVC Embólico - Anticoagulantes

Authors' Contributions

BBP: conceptualization, formal analysis, investigation, methodology, project administration, writing – original draft, writing – review & editing; KSZ: conceptualization, formal analysis, methodology, project administration, supervision, writing – review & editing; AS: formal analysis, methodology, project administration, resources, writing – review & editing; ZY: formal analysis, methodology, validation, writing – review & editing; JOF, LHS: conceptualization, formal analysis, methodology, project administration, supervision, writing – review & editing.


Support

BBP: has a visiting scholarship at the Massachusetts General Hospital and Harvard Medical School, and was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. KSZ: reports grant funding from Massachusetts General Hospital Execute Committee on Research, the Controlled Risk Insurance Company, the American College of Emergency Physicians, and the National Institutes of Health / National Institute of Neurological Disorders and Stroke; she also reports honoraria for editorial activities from the American Heart Association and UpToDate. AS: is funded by grants from the NIH-NINDS and CRICO-RMF. JOF: was financed in part by a Productivity Grant from the Brazilian National Council for Scientific and Technological Development (CNPq). LHS: served as a scientific consultant regarding trial design and conduct to Genentech for late window thrombolysis and as a Member of the steering committee (TIMELESS NCT03785678); as consultant on user interface design and usability to LifeImage; as a stroke systems of care consultant to the Massachusetts Dept of Public Health; as a member of a Data Safety Monitoring Boards (DSMB) for Penumbra (MIND NCT03342664) and for Diffusion Pharma PHAST-TSC NCT03763929); as National PI for stroke prevention in AF for Medtronic (Stroke AF NCT02700945); as Site PI, StrokeNet Network NINDS (New England Regional Coordinating Center U24NS107243) and as a CME lecturer on stroke systems of care and improving time to thrombolysis for PRIME Education and Boehringer-Ingelheim.




Publication History

Received: 18 September 2022

Accepted: 16 March 2023

Article published online:
19 June 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Wolf PA, Dawber TR, Thomas Jr HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28 (10) 973-977
    CrossrefPubMedSearch in Google Scholar
  • 2 Wang L, Ze F, Li J. et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. Heart 2021; 107 (11) 881-887
    CrossrefPubMedSearch in Google Scholar
  • 3 Silva Pinto S, Teixeira A, Henriques TS, Monteiro H, Martins C. AF-React study: atrial fibrillation management strategies in clinical practice-retrospective longitudinal study from real-world data in Northern Portugal. BMJ Open 2021; 11 (03) e040404
    CrossrefPubMedSearch in Google Scholar
  • 4 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
    CrossrefPubMedSearch in Google Scholar
  • 5 Friberg J, Scharling H, Gadsbøll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003; 92 (12) 1419-1423
    CrossrefPubMedSearch in Google Scholar
  • 6 Krijthe BP, Kunst A, Benjamin EJ. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34 (35) 2746-2751
    CrossrefPubMedSearch in Google Scholar
  • 7 Marcolino MS, Palhares DMF, Benjamin EJ, Ribeiro AL. Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. Europace 2015; 17 (12) 1787-1790
    CrossrefPubMedSearch in Google Scholar
  • 8 Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112 (08) 1142-1147
    CrossrefPubMedSearch in Google Scholar
  • 9 Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG. Stroke Prevention in Atrial Fibrillation Investigators. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996; 46 (01) 238-240
    CrossrefPubMedSearch in Google Scholar
  • 10 Hart RG, Pearce LA, Miller VT. et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10 (01) 39-43
    CrossrefPubMedSearch in Google Scholar
  • 11 Paciaroni M, Agnelli G, Caso V. et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke 2019; 50 (08) 2168-2174
    CrossrefPubMedSearch in Google Scholar
  • 12 Schachter ME, Tran HA, Anand SS. Oral anticoagulants and non-cardioembolic stroke prevention. Vasc Med 2008; 13 (01) 55-62
    CrossrefPubMedSearch in Google Scholar
  • 13 Diener H-C, Sacco RL, Easton JD. et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med 2019; 380 (20) 1906-1917
    CrossrefPubMedSearch in Google Scholar
  • 14 Hart RG, Sharma M, Mundl H. et al; NAVIGATE ESUS Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 2018; 378 (23) 2191-2201
    Search in Google Scholar
  • 15 Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke 2001; 32 (12) 2828-2832
    CrossrefPubMedSearch in Google Scholar
  • 16 Hert L, Polymeris AA, Schaedelin S. et al. Small vessel disease is associated with an unfavourable outcome in stroke patients on oral anticoagulation. Eur Stroke J 2020; 5 (01) 63-72
    CrossrefPubMedSearch in Google Scholar
  • 17 Seiffge DJ, Wilson D, Ambler G. et al. Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants. J Neurol Neurosurg Psychiatry 2021; 92 (08) 805-814
    CrossrefPubMedSearch in Google Scholar
  • 18 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
    CrossrefPubMedSearch in Google Scholar
  • 19 Adams Jr HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24 (01) 35-41
    Search in Google Scholar
  • 20 Henninger N, Goddeau Jr RP, Karmarkar A, Helenius J, McManus DD. Atrial Fibrillation Is Associated With a Worse 90-Day Outcome Than Other Cardioembolic Stroke Subtypes. Stroke 2016; 47 (06) 1486-1492
    CrossrefPubMedSearch in Google Scholar
  • 21 Adams Jr HP, Davis PH, Leira EC. et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53 (01) 126-131
    CrossrefPubMedSearch in Google Scholar
  • 22 Amaral CHD, Amaral AR, Nagel V. et al. Incidence and functional outcome of atrial fibrillation and non-atrial fibrillation- related cardioembolic stroke in Joinville, Brazil: a population-based study. Arq Neuropsiquiatr 2017; 75 (05) 288-294
    CrossrefPubMedSearch in Google Scholar
  • 23 Rose AJ, Goldberg R, McManus DD. et al. Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration. J Am Heart Assoc 2019; 8 (17) e012646
    CrossrefPubMedSearch in Google Scholar
  • 24 Hsu JC, Maddox TM, Kennedy KF. et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. JAMA Cardiol 2016; 1 (01) 55-62
    CrossrefPubMedSearch in Google Scholar
  • 25 Bartholomay E, Polli I, Borges AP. et al. Prevalence of oral anticoagulation in atrial fibrillation. Clinics (São Paulo) 2014; 69 (09) 615-620
    CrossrefPubMedSearch in Google Scholar
  • 26 Kunt R, Kutluk MK, Tiftikçioğlu Bİ. et al. Comparison of conventional and modern methods in determining ischemic stroke etiology by general and stroke neurologists. Turk J Med Sci 2019; 49 (01) 170-177
    PubMedSearch in Google Scholar
  • 27 Zhang Q, Yang Y, Saver JL. Discharge destination after acute hospitalization strongly predicts three month disability outcome in ischemic stroke. Restor Neurol Neurosci 2015; 33 (05) 771-775
    PubMedSearch in Google Scholar
  • 28 Asaithambi G, Tipps ME. Predictive value of discharge destination for 90-day outcomes among ischemic stroke patients eligible for endovascular treatment: Post-hoc analysis of DEFUSE 3. J Stroke Cerebrovasc Dis 2020; 29 (08) 104902
    CrossrefPubMedSearch in Google Scholar
  • 29 ElHabr AK, Katz JM, Wang J. et al. Predicting 90-day modified Rankin Scale score with discharge information in acute ischaemic stroke patients following treatment. BMJ Neurol Open 2021; 3 (01) e000177
    CrossrefPubMedSearch in Google Scholar